Taysha Gene Therapies, Inc.

Welcome to the Tayshia Gene Therapy's fourth quarter and full year 2021 financial results and corporate update. At this time, all participants are in listen-only mode. Following management's prepared remarks, we'll hold a brief question and answer session. As a reminder, this call is being recorded today, March 31st, 2022. I'll now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.

Good morning and welcome to Tayshia's fourth quarter and full year 2021 financial results and corporate update conference call. Joining me on today's call are Ari Session II, Tayshia's president, founder, and CEO, Dr. Suresh Prasad, chief medical officer and head of R&D, and Cameron Alam, chief financial officer. After our formal remarks, we will conduct a question and answer session and instructions will follow at that time. Earlier today, Tayshia issued a press release announcing financial results for the fourth quarter and full year ended December 31st, 2021. A copy of this press release is available on the company's website and through our SEC filings. Please note that on today's call, we will be making forward-looking statements, including statements relating to the safety and efficacy and the therapeutic and commercial potential of our investigational product candidates. These statements may include the effects of timing and results of clinical trials for our product candidates, our expectations regarding the data necessary to support regulatory approval of TASHA 120, the regulatory status and market opportunity for our clinical programs, as well as Tayshia's manufacturing plans. This call may also contain forward-looking statements relating to Tayshia's growth and future operating results, discovery and development of product candidates, strategic alliances, intellectual property, cash runway, and implementation and potential impacts of our strategic pipeline prioritization initiatives, as well as matters that are not of historical facts or information. Various risks may cause patients' actual results to differ materially from those stated or implied in such forward-looking statements. These risks include uncertainties related to the timing and results of clinical trials and preclinical studies of our product candidates, our dependence upon strategic alliances and other third-party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties, and the requirement of substantial funding to conduct our research and development activities. For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the Securities and Exchange Commission. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, March 31, 2022. TASHA undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities law. With that, I'd now like to turn the call over to our president, founder, and CEO, R.A. Session II. R.A.?

Thank you, Kim. Good morning, and welcome, everyone, to our call. 2021 was a year of accomplishment that included positive data from three clinical programs, including GAN, GM2 gangliosidosis, and CLN7 disease. We are sharpening our strategic focus to prioritize key value-driving registration-directed programs in GAN, which has an estimated addressable patient population of 5,000 worldwide, and Rett Syndrome, which affects over 350,000 patients worldwide. To increase operational efficiency, activities for other ongoing clinical programs will be minimized and all other research and development will be paused. As a result, we have reduced our workforce by approximately 35%. Our strategic pipeline prioritization, along with existing cash and financing under our current debt facility, is expected to extend cash runway into the fourth quarter of 2023. We look forward to our continued execution across our clinical and regulatory strategies, and we'll update you on progress throughout the remainder of the year. I will now turn the call over to Suyesh to provide a more detailed update on our clinical program.